RecruitingPhase 1NCT06867393

Safety, Tolerability, and Pharmacokinetics of HL-003 in Healthy Subjects

Phase I Clinical Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of HL-003 in Healthy Subjects

Sponsor

Shanghai Kechow Pharma, Inc.

Enrollment

52 participants

Start Date

Feb 28, 2025

Study Type

INTERVENTIONAL

Conditions

Healthy Subjects

Summary

This clinical study aims to evaluate the safety, tolerability, and pharmacokinetic characteristics of HL-003 tablets in healthy subjects. It is conducted in two sequential clinical phases: single-dose and multiple-dose escalation.

Eligibility

Min Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HL-003 tablet and a drug called HL-003 tablet Placeco for people with healthy subjects. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.